Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide  that was being developed for inflammatory bowel diseases (IBD). ... Read more

Stock Quote

PTGX (Common Stock)
$8.820.00 (0.00%)
Exchange :NASDAQ
Volume :0
Today's Open$0.00
Previous Close$8.82
Data as of October 18, 2018 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $8.82 with a 52 week high of $23.97 and a 52 week low of $5.50.

Recent Press Releases

October 08, 2018

Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting read more

September 27, 2018

Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 read more

September 24, 2018

Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1 read more

Upcoming Events


Download Documentation Investor Presentation
Data provided by Nasdaq. Minimum 15 minutes delayed.